GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
H

Humasis Co 205470.KQ · KRW

Health Care · KOSDAQ · 🇰🇷 South Korea

Compare

2,235

+2.76%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Humasis Co

Its shares trade on KOSDAQ under the ticker 205470.KQ. It has been listed since 1 December 2014. In the fiscal year to 31 December 2025, it reported revenue of ₩30.11bn and a net loss of ₩15.62bn. At that date it held total assets of ₩327.03bn and shareholders' equity of ₩215.06bn.

Humasis Co., Ltd. engages in developing rapid test kits and point-of-care testing instruments. The company is headquartered in Anyang, Gyeonggi-Do. The company went IPO on 2014-12-01. The firm is engaged in the manufacture and sale of immunoquantitative analysis devices, myocardial infarction test equipment, infectious disease detection devices, hormone test devices, cancer marker test devices and other products. In addition, the Company is engaged in the research and development of biomaterials and other products. The firm sells its products within domestic market and to overseas markets. The firm was established in 2000 and is located in Gunpo-si, Gyeonggi-do, South Korea.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Health Care Equipment & Supplies
Listed since
1 Dec 2014
Employees
241
Website
humasis.com ↗

Leadership

Pay as last reported

  • Seong Gon KimChief Executive Officer, Director, since 2023
  • Hyeong Seon KimInternal Auditor
  • Gwang Sik ChoDirector
  • Seung Hun KangDirector
  • Jeong Tae KimDirector
  • Seok Jae LeeDirector
  • Yin Gyu ChoNon-Executive Independent Director
  • Mr. Byeong Ryeol NohNon-Executive Independent Director
  • Seong Cheol YimNon-Executive Independent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Rapid test kits and point-of-care testing instruments are key products for the company.
  • Immunoquantitative analysis devices and cancer marker test devices support diverse medical needs.
  • Research and development of biomaterials enhances the firm's technological capabilities significantly.

Weaknesses

  • The small workforce of 241 employees limits large-scale production capacity.
  • Reliance on domestic market sales reduces immediate international revenue diversity.
  • Establishment in 2000 means older technology may require frequent updates.

Opportunities

  • Selling products to overseas markets expands the potential customer base globally.
  • Infectious disease detection devices address growing global health monitoring requirements.
  • Hormone test devices offer new avenues for specialized diagnostic market growth.

Threats

  • Competitors in the health care sector may offer cheaper rapid test kits.
  • Economic downturns in South Korea could reduce domestic medical device spending.
  • Regulatory changes in overseas markets might hinder the sale of test equipment.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.